[Efficacy and safety of bulevirtide in patients with chronic hepatitis D and compensated cirrhosis].

P O Bogomolov Vladimir Ivashkin A O Bueverov Igor Maev O I Sagalova S S Sleptsova N D Yushuk D A Gusev K V Zhdanov Vladimir P Chulanov

Published in: Terapevticheskii arkhiv (2021)

Bulevirtide is recommended as the first line of treatment for chronic hepatitis D in patients with compensated cirrhosis in monotherapy and combination with PEG-IFN.

Keyphrases

combination therapy
immune response
drug delivery
open label
randomized controlled trial
drug induced